Banner of CND: United Nations Commission on Narcotic Drugs, policymaking body of the United Nations system with prime responsibility for drug-related matters
The resolutions and decisions database offers for full text search and sorting:
| Arabic | Chinese | English | French | Russian | Spanish |
Statement of the Commission on Narcotic Drugs on the impact of the coronavirus disease (COVID-19) pandemic on the implementation of Member States’ joint commitments to address and counter all aspects of the world drug problem
Promoting alternative development as a development-oriented drug control strategy, including in the context of the coronavirus disease (COVID-19) pandemic and its consequences
Promoting scientific evidence-based, quality, affordable and comprehensive drug prevention, treatment, sustained recovery and related support services
Improving data collection on, and responses to, the harmful effects of the non-medical use of pharmaceuticals containing narcotic drugs, psychotropic substances or new psychoactive substances
Facilitating access to comprehensive, scientific evidence-based drug demand reduction services and related measures, including for people impacted by social marginalization
Inclusion of isotonitazene in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of CUMYL-PEGACLONE in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of MDMB-4en-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 3-methoxyphencyclidine in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of diphenidine in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of clonazolam in Schedule IV of the Convention on Psychotropic Substances of 1971
Inclusion of diclazepam in Schedule IV of the Convention on Psychotropic Substances of 1971
Inclusion of flubromazolam in Schedule IV of the Convention on Psychotropic Substances of 1971
| Arabic | Chinese | English | French | Russian | Spanish |
International cooperation to address and counter the world drug problem
Report of the Commission on Narcotic Drugs on its reconvened sixty-second session
Report of the Commission on Narcotic Drugs on its sixty-third session and provisional agenda for its sixty-fourth session
Report of the International Narcotic Control Board
Promoting efforts by Member States to address and counter the world drug problem, in particular supply reduction-related measures, through effective partnerships with private sector entities
Promoting and improving the collection and analysis of reliable and comparable data to strengthen balanced, integrated, comprehensive, multidisciplinary and scientific evidence-based responses to the world drug problem
Promoting awareness-raising, education and training as part of a comprehensive approach to ensuring access to and the availability of internationally controlled substances for medical and scientific purposes and improving their rational use
Promoting the involvement of youth in drug prevention efforts
Promoting alternative development as a development-oriented drug control strategy
Inclusion of methyl alpha-phenylacetoacetate (MAPA), including its optical isomers, in Table I of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988
Inclusion of crotonylfentanyl in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of valerylfentanyl in Schedule I of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol
Inclusion of DOC in Schedule I of the of the Convention on Psychotropic Substances of 1971
Inclusion of AB-FUBINACA in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 5F-AMB-PINACA (5F-AMB, 5F-MMB-PINACA) in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 5F-MDMB-PICA (5F-MDMB-2201) in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 4F-MDMB-BINACA in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of 4-CMC (4-chloromethcathinone, clephedrone) in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of N-ethylhexedrone in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of alpha-PHP in Schedule II of the Convention on Psychotropic Substances of 1971
Inclusion of flualprazolam in Schedule IV of the Convention on Psychotropic Substances of 1971
Inclusion of etizolam in Schedule IV of the Convention on Psychotropic Substances of 1971
Changes in the scope of control of substances: proposed scheduling recommendations by the World Health Organization on cannabis and cannabis-related substances
Improved and streamlined annual report questionnaire
